Grown Rogue International (GRUSF) Interest Expenses (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Interest Expenses came in at $768885.0 in Q1 2026, up 749.09% year-on-year from $90554.1 in Q1 2025, and down 100.0% quarter-over-quarter from $400.9 billion in Q4 2025.
Grown Rogue International (GRUSF) Interest Expenses (2009 - 2026) Analysis & Trends
Grown Rogue International's Interest Expenses history runs 18 years deep, the most recent figure standing at $768885.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 749.09% year-over-year to $768885.0 in Q1 2026; TTM through Mar 2026 was $768885.0, a 100.0% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, down 59.46% from the prior year.
- Interest Expenses fell to $768885.0 in Q1 2026 per GRUSF's latest filing, from $400.9 billion in the prior quarter.
- Across five years, Interest Expenses topped out at $400.9 billion in Q4 2025 and bottomed at -$125.2 billion in Q3 2025.
- The 5-year median for Interest Expenses is -$114660.0 (2022), against an average of $13.4 billion.
- Across the five-year window, Interest Expenses sank 1444.67% in 2022 and soared 749.09% in 2026, its largest moves.
- Year by year, Interest Expenses stood at -$114660.0 in 2022, then sank by 136.45% to -$271112.0 in 2023, then tumbled by 37527563.84% to -$101.7 billion in 2024, then soared by 494.07% to $400.9 billion in 2025, then tumbled by 100.0% to $768885.0 in 2026.
- Per Business Quant, the three latest GRUSF Interest Expenses figures stand at $768885.0 (Q1 2026), $400.9 billion (Q4 2025), and -$125.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 768,885.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 768,885.00 |
| Mar 31, 2026 | 768,885.00 |
| Dec 31, 2025 | 400.94 Bn |
| Dec 31, 2025 | 400.94 Bn |
| Sep 30, 2025 | -125.20 Bn |
| Sep 30, 2025 | -125.20 Bn |
| Jun 30, 2025 | -157,283.00 |
| Jun 30, 2025 | -157,283.00 |
| Mar 31, 2025 | -118,456.00 |
| Mar 31, 2025 | -118,456.00 |
| Sep 30, 2024 | -101.74 Bn |
| Sep 30, 2024 | -101.74 Bn |
| Jun 30, 2024 | -58,225.11 |
| Jun 30, 2024 | -58,225.11 |
| Mar 31, 2024 | -89,687.00 |
| Mar 31, 2024 | -89,687.00 |
| Oct 31, 2023 | -271,112.00 |
| Oct 31, 2023 | -271,112.00 |
| Jul 31, 2023 | -185,686.00 |
| Jul 31, 2023 | -185,686.00 |